Olaparib resistance management

Olaparib belongs to a class of drugs called PARP inhibitors. PARP inhibitors interfere with the DNA damage response in tumor cells, particularly those with defects in a specific type of DNA repair called homologous recombination. Lynparza is commonly used to treat certain hereditary breast and ovarian cancers. Sometimes, however, patients may develop resistance to olaparib, causing the drug to lose its effectiveness.

Drug resistance is often related to genetic mutations in tumors. If a patient develops resistance to olaparib, doctors may adjust the dose or combine drugs to improve the treatment effect. MG18L is a newly identified oHSV activity that was reported to proteasomally degrade RAD51 in a synthetic lethal manner in vivo and in vitro and sensitize glioblastoma stem cells (GSCs) to PARPi killing. The combination of olaparibandMG18L greatly increased the survival of PARPi-sensitive and resistant GSC-derived tumors. However, everyone’s physique is different and their resistance to drugs is also different. If you feel unwell, please inform your doctor in time.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.